Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03680586 · ClinicalTrials.gov registry record · Early Phase 1
Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma
A Early Phase 1 study of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03680586 is a Early Phase 1 study of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 25 participants. The trial reports 1 study location across 1 state.
The verdict
NCT03680586, a Early Phase 1 study of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies how well ultra low-dose radiation therapy works in treating patients with stage I-IV stomach mucosa-associated lymphoid tissue (MALT) lymphoma. Ultra low-dose radiation therapy may be able to kill tumor cells and shrink tumors while having fewer side effects in patients with MALT lymphoma.
Conditions Studied
Interventions
- DRUG Radiation Therapy
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-02-04 |
| Est. Completion | 2028-04-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03680586
The ClinicalTrials.gov registry entry for NCT03680586 describes a study currently listed as active not recruiting, categorized as Early Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Gastric Mucosa-Associated Lymphoid Tissue Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which Radiation Therapy is the first listed.
NCT03680586 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT03680586 about?
NCT03680586 is a clinical study titled "Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma". This trial studies how well ultra low-dose radiation therapy works in treating patients with stage I-IV stomach mucosa-associated lymphoid tissue (MALT) lymphoma. Ultra low-dose radiation therapy may be able to kill tumor cells and shrink tumors while having fewer side effects in patients with MALT ...
What is the current status of trial NCT03680586?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2019-02-04. Estimated completion is 2028-04-30.
What conditions does trial NCT03680586 study?
This clinical trial studies the following conditions: Gastric Mucosa-Associated Lymphoid Tissue Lymphoma.
What interventions are being tested in trial NCT03680586?
The interventions under investigation include: Radiation Therapy (DRUG).
Who is sponsoring clinical trial NCT03680586?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03680586 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.